Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_4
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

unknown1
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 42 (66.7%)

Trials by Status

unknown133%
not_yet_recruiting133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_1

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

NCT07295873
completedphase_4

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

NCT03356834
unknownphase_4

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

NCT04202536

Clinical Trials (3)

Showing 3 of 3 trials
NCT07295873Phase 1

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

Not Yet Recruiting
NCT03356834Phase 4

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

Completed
NCT04202536Phase 4

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3